Skip to main
HUM

Humana (HUM) Stock Forecast & Price Target

Humana (HUM) Analyst Ratings

Based on 18 analyst ratings
Hold
Strong Buy 11%
Buy 22%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Humana's financial outlook is bolstered by an increased 2025 EPS estimate of $17.06, reflecting strong second-quarter results and updated guidance. The company anticipates year-over-year earnings growth in 2027, supported by effective margin initiatives, despite stable performance in its Stars program. Additionally, Humana’s superior Medicare Advantage star rating positions the company favorably amidst evolving regulatory and reimbursement landscapes, reinforcing its competitive advantage in the market.

Bears say

The financial outlook for Humana indicates potential challenges, with management projecting a slight decline in earnings per share (EPS) for 2026 compared to 2025, primarily due to headwinds related to Medicare Star ratings. The company faces a variety of downside risks, including increased competition in Medicare Advantage, inadequate reimbursement rates, and declining membership in its Prescription Drug Plans, all of which could adversely affect future growth. Additionally, estimates for FY27 EPS have been conservatively adjusted, anticipating a shortfall of approximately 10% driven by increased investment aimed at recovering Star ratings performance.

Humana (HUM) has been analyzed by 18 analysts, with a consensus rating of Hold. 11% of analysts recommend a Strong Buy, 22% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Humana and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Humana (HUM) Forecast

Analysts have given Humana (HUM) a Hold based on their latest research and market trends.

According to 18 analysts, Humana (HUM) has a Hold consensus rating as of Jan 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $292.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $292.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Humana (HUM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.